Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All liver tumors that require resection of more than two segments of the liver.~* Age ≥20 and ≤80~* General performance status: the Karnofsky score\> 70% or ECOG 0-1~Exclusion Criteria:~* Hepatic duct reconstruction was performed~* ASA (American society of anesthesiologists' physical status classification) score: ≥3~* Patients with drug or alcohol addiction~* Patients showing low compliance~* Patients who not want to involve the clinical trial~* Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): hepatectomy without Gabexate Mesilate
- Preoperative Gabexate Mesilate group (Type: EXPERIMENTAL): Gabexate Mesilate administered from the preoperative day
- Intraoperative Gabexate Mesilate group (Type: EXPERIMENTAL): Gabexate Mesilate administered from the operative day

Based on this trial design, predict the completion outcome and termination type (if applicable).